Product Description
Mechanisms of Action: TLR4 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Respiratory Insufficiency|Sepsis|Shock, Septic
Phase 2: Hepatitis C, Chronic|Liver Cirrhosis, Alcoholic|Liver Failure, Acute|Hepatitis, Alcoholic|Acute-On-Chronic Liver Failure|Respiratory Insufficiency|Kidney Diseases|Acute Kidney Injury|Liver Cirrhosis|Hepatic Insufficiency|End Stage Liver Disease|Hepatitis, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| G-TAK-ES-01 | P2 |
Withdrawn |
Liver Cirrhosis|Liver Failure, Acute|Acute Kidney Injury|Respiratory Insufficiency|Kidney Diseases |
2025-01-31 |
|
| TAK-242-2001 | P2 |
Unknown status |
Hepatic Insufficiency|End Stage Liver Disease|Acute-On-Chronic Liver Failure|Hepatitis, Chronic|Liver Failure, Acute|Hepatitis, Alcoholic |
2022-12-01 |
24% |
| Phase 2a Study of TAK-242 to Treat Acute-on-Chronic Liver Failure | P2 |
Unknown status |
Liver Cirrhosis, Alcoholic|Liver Failure, Acute|Hepatitis, Alcoholic|Acute-On-Chronic Liver Failure|Hepatitis C, Chronic |
2022-04-28 |
|
| JapicCTI-080588 | P3 |
Terminated |
Respiratory Insufficiency|Sepsis |
2012-11-01 |